Immune-modulators to combat hepatitis B virus infection: From IFN-α to novel investigational immunotherapeutic strategies

Antiviral Research

Volumn 122, Issue , 2015, Pages 69-81

  Isorce, Nathalie ^a,b   Lucifora, Julie ^a,b   Zoulim, Fabien ^a,b,c,d   Durantel, David ^a,b,c  

^a CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c LabEx DEVweCAN   (France)

^d CROIX ROUSSE HOSPITAL   (France)

Author keywords

Cytokines chemokines; Hepatitis B virus; Immune modulators; Immunotherapy; Interferon

Indexed keywords

ALDESLEUKIN; ALPHA INTERFERON; ALPHAN3 INTERFERON; BETA INTERFERON; BETA1A INTERFERON; CHEMOKINE; CONSENSUS INTERFERON; CYT 107; CYTOKINE; GAMMA INTERFERON; GAMMA1B INTERFERON; HEPATITIS B ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 28A; INTERLEUKIN 29; INTERLEUKIN 6; OPRELVEKIN; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTIVIRUS AGENT; IMMUNOLOGIC FACTOR; RECOMBINANT PROTEIN;

ADJUVANT THERAPY; ANTIVIRAL ACTIVITY; DRUG INDICATION; HEPATITIS B; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOSYNTHESIS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; IMMUNOLOGY; ORGANIZATION; PATHOLOGY; VIROLOGY;

HEPATITIS B VIRUS;

ANIMALS; ANTIVIRAL AGENTS; CHEMOKINES; CONGRESSES AS TOPIC; CYTOKINES; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; INTERFERON-ALPHA; RECOMBINANT PROTEINS;

EID: 84940172833     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.08.008     Document Type: Review

References (111)

1. C.M.I. Ahmed, and H.M. Johnson IFN-γ and its receptor subunit IFNGR1 are recruited to the IFN-γ-activated sequence element at the promoter site of IFN-γ-activated genes: evidence of transactivational activity in IFNGR1 J. Immunol. 177 2006 315 321
2. L. Allweiss, T. Volz, M. Lutgehetmann, K. Giersch, T. Bornscheuer, A.W. Lohse, J. Petersen, H. Ma, K. Klumpp, S.P. Fletcher, and M. Dandri Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration J. Hepatol. 60 2014 500 507
3. B.R. Bacon, M.L. Shiffman, F. Mendes, R. Ghalib, T. Hassanein, G. Morelli, S. Joshi, K. Rothstein, P. Kwo, and N. Gitlin Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results Hepatology 49 2009 1838 1846
4. A. Begitt, M. Droescher, T. Meyer, C.D. Schmid, M. Baker, F. Antunes, K.P. Knobeloch, M.R. Owen, R. Naumann, T. Decker, and U. Vinkemeier STAT1-cooperative DNA binding distinguishes type 1 from type 2 interferon signaling Nat. Immunol. 15 2014 168 176
5. L. Belloni, L. Allweiss, F. Guerrieri, N. Pediconi, T. Volz, T. Pollicino, J. Petersen, G. Raimondo, M. Dandri, and M. Levrero IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome J. Clin. Invest. 122 2012 529 537
6. F. Bouezzedine, O. Fardel, and P. Gripon Interleukin 6 inhibits HBV entry through NTCP down regulation Virology 481 2015 34 42
7. A. Brass, L. Frelin, D.R. Milich, M. Sallberg, and G. Ahlen Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination Mol. Ther.:J. Am. Soc. Gene Ther. 23 2015 578 590
8. W.H. Caselmann, M. Meyer, S. Scholz, P.H. Hofschneider, and R. Koshy Type I interferons inhibit hepatitis B virus replication and induce hepatocellular gene expression in cultured liver cells J. Infect. Dis. 166 1992 966 971
9. V.J. Cavanaugh, L.G. Guidotti, and F.V. Chisari Interleukin-12 inhibits hepatitis B virus replication in transgenic mice J. Virol. 71 1997 3236 3243
10. J. Chang, and J.T. Guo Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure Antiviral Res. 121 2015 152 159
11. J.Y. Chen, E.R. Feeney, and R.T. Chung HCV and HIV co-infection: mechanisms and management Nat. Rev. Gastroenterol. Hepatol. 11 2014 362 371
12. Y.-H. Chow, B.-L. Chiang, Y.-L. Lee, W.-K. Chi, W.-C. Lin, Y.-T. Chen, and M.-H. Tao Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes J. Immunol. 160 1998 1320 1329
13. A. Ciancio, and M. Rizzetto Chronic hepatitis D at a standstill: where do we go from here? Nat. Rev. Gastroenterol. Hepatol. 11 2014 68 71
14. R.A. Colvin, T. Tanwandee, T. Piratvisuth, S. Thongsawat, A.J. Hui, H. Zhang, H. Ren, P.J. Chen, W.L. Chuang, A. Sobhonslidsuk, R. Li, Y. Qi, J. Praestgaard, Y. Han, J. Xu, D.S. Stein, and A.A.S. Group Randomized, controlled pharmacokinetic and pharmacodynamic evaluation of albinterferon in patients with chronic hepatitis B infection J. Gastroenterol. Hepatol. 30 2015 184 191
15. P. Couzigou, S. Pérusat, M. Bourlière, P. Trimoulet, T. Poynard, V. Leroy, P. Marcellin, J. Foucher, J.-P. Bronowicki, G. Chêne, and A.H.G.T. Group Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI) J. Gastroenterol. Hepatol. 28 2013 329 334
16. J. Crouse, U. Kalinke, and A. Oxenius Regulation of antiviral T cell responses by type I interferons Nat. Rev. Immunol. 15 2015 231 242
17. M. Dalod, R. Chelbi, B. Malissen, and T. Lawrence Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming EMBO J. 33 2014 1104 1116
18. L. Dumoutier, A. Tounsi, T. Michiels, C. Sommereyns, S.V. Kotenko, and J.C. Renauld Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling J. Biol. Chem. 279 2004 32269 32274
19. D. Durantel, and F. Zoulim Interplay between hepatitis B virus and TLR2-mediated innate immune responses: can restoration of TLR2 functions be a new therapeutic option? J. Hepatol. 57 2012 486 489
20. EASL EASL clinical practice guidelines: management of chronic hepatitis b virus infection J. Hepatol. 57 2012 167 185
21. A. Egli, D.M. Santer, D. O'Shea, D.L. Tyrrell, and M. Houghton The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections Emerging Microbes Infect. 3 2014 e51
22. V. Escuret, A. Martin, D. Durantel, R. Parent, O. Hantz, C. Trepo, T. Menguy, E. Bottius, J. Dardy, J. Maral, J.L. Escary, and F. Zoulim Novel alpha interferon (IFN-alpha) variant with improved inhibitory activity against hepatitis C virus genotype 1 replication compared to IFN-alpha2b therapy in a subgenomic replicon system Antimicrob. Agents Chemother. 50 2006 3984 3991
23. J.J. Feld The beginning of the end: what is the future of interferon therapy for chronic hepatitis C? Antiviral Res. 105 2014 32 38
24. G.R. Foster Pegylated interferons for the treatment of chronic hepatitis C: pharmacological and clinical differences between peginterferon-alpha-2a and peginterferon-alpha-2b Drugs 70 2010 147 165
25. E.J. Gane, Y.-S. Lim, S.C. Gordon, K. Visvanathan, E. Sicard, R.N. Fedorak, S. Roberts, B. Massetto, Z. Ye, S. Pflanz, K.L. Garrison, A. Gaggar, G. Mani Subramanian, J.G. McHutchison, S. Kottilil, B. Freilich, C.S. Coffin, W. Cheng, and Y.J. Kim The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection J. Hepatol. 63 2015 320 328
26. R.G. Gish, B.D. Given, C.-L. Lai, S.A. Locarnini, J.Y.N. Lau, D.L. Lewis, and T. Schluep Chronic hepatitis B: virology, natural history, current management and a glimpe at future opportunities Antiviral Res. 121 2015 47 58
27. E. Gordien, O. Rosmorduc, C. Peltekian, F. Garreau, C. Brechot, and D. Kremsdorf Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein J. Virol. 75 2001 2684 2691
28. M. Gruffaz, B. Testoni, S. Luangsay, M. Ait-Goughoulte, M.A. Petit, H. Ma, K. Klumpp, H. Javanbakht, D. Durantel, and F. Zoulim Hepatitis B core (HBC) protein is a key and very early negative regulator of the interferon response J. Hepatol. 58 2013 S155 S156
29. L.G. Guidotti, S. Guilhot, and F.V. Chisari Interleukin-2 and alpha/beta interferon down-regulate hepatitis B virus gene expression in vivo by tumor necrosis factor-dependent and -independent pathways J. Virol. 68 1994 1265 1270
30. L.G. Guidotti, P. Borrow, M.V. Hobbs, B. Matzke, I. Gresser, M.B. Oldstone, and F.V. Chisari Viral cross talk: intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver PNAS 93 1996 4589 4594
31. L.G. Guidotti, T. Ishikawa, M.V. Hobbs, B. Matzke, R. Schreiber, and F.V. Chisari Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes Immunity 4 1996 25 36
32. L.G. Guidotti, R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F.V. Chisari Viral clearance without destruction of infected cells during acute HBV infection Science 284 1999 825 829
33. L.G. Guidotti, A. Morris, H. Mendez, R. Koch, R.H. Silverman, B.R. Williams, and F.V. Chisari Interferon-regulated pathways that control hepatitis B virus replication in transgenic mice J. Virol. 76 2002 2617 2621
34. J. Haybaeck, N. Zeller, M.J. Wolf, A. Weber, U. Wagner, M.O. Kurrer, J. Bremer, G. Iezzi, R. Graf, P.-A. Clavien, R. Thimme, H. Blum, S.A. Nedospasov, K. Zatloukal, M. Ramzan, S. Ciesek, T. Pietschmann, P.N. Marche, M. Karin, M. Kopf, J.L. Browning, A. Aguzzi, and M. Heikenwalder A lymphotoxin-driven pathway to hepatocellular carcinoma Cancer Cell 16 2009 295 308
35. B. Heidrich, C. Yurdaydin, G. Kabacam, B.A. Ratsch, K. Zachou, B. Bremer, G.N. Dalekos, A. Erhardt, F. Tabak, K. Yalcin, S. Gurel, S. Zeuzem, M. Cornberg, C.T. Bock, M.P. Manns, H. Wedemeyer, and H.-S. Group Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta Hepatology 60 2014 87 97
36. T. Heise, L.G. Guidotti, V.J. Cavanaugh, and F.V. Chisari Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice J. Virol. 73 1999 474 481
37. M. Hösel, M. Quasdorff, K. Wiegmann, D. Webb, U. Zedler, M. Broxtermann, R. Tedjokusumo, K. Esser, S. Arzberger, C.J. Kirschning, A. Langenkamp, C. Falk, H. Büning, S. Rose-John, and U. Protzer Not interferon, but interleukin-6 controls early gene expression in hepatitis B virus infection Hepatology 50 2009 1773 1782
38. M. Isogawa, M.D. Robek, Y. Furuichi, and F.V. Chisari Toll-like receptor signaling inhibits hepatitis B virus replication in vivo J. Virol. 79 2005 7269 7272
39. A. Issacs, and J. Lindenmann Virus interference I: the interferon Proc. R. Soc. Lond. 147 1957 258 267
40. A. Issacs, and J. Lindenmann Virus interference, II: some properties of interferon Proc. R. Soc. Lond. 147 1957 268 273
41. Isorce, N., Testoni, B., Locatelli, M., Luangsay, S., Fresquet, J., Zoulim, F., Durantel, D., submitted for publication. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus. Antiviral Res.
42. A. Iwasaki, and R. Medzhitov Innate responses to viral infections D. Knipe, P. Howley (Eds.), Fields Virology 2013 Lippincott Williams & Wilkins Philadelphia 189 213
43. H.L.A. Janssen, M. van Zonneveld, H. Senturk, S. Zeuzem, U.S. Akarca, Y. Cakaloglu, C. Simon, T.M.K. So, G. Gerken, R.A. de Man, H.G.M. Niesters, P. Zondervan, B. Hansen, and S.W. Schalm Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial Lancet 365 2005 123 129
44. J. Jo, A.T. Tan, J.E. Ussher, E. Sandalova, X.Z. Tang, A. Tan-Garcia, N. To, M. Hong, A. Chia, U.S. Gill, P.T. Kennedy, K.C. Tan, K.H. Lee, G. De Libero, A.J. Gehring, C.B. Willberg, P. Klenerman, and A. Bertoletti Toll-like receptor 8 agonist and bacteria trigger potent activation of innate immune cells in human liver PLoS Pathogens 10 2014 e1004210
45. K.W. Kang, Y. Wagley, H.W. Kim, Y.R. Pokharel, Y.Y. Chung, I.Y. Chang, J.J. Kim, J.S. Moon, Y.K. Kim, S.Y. Nah, H.S. Kang, and J.W. Oh Novel role of IL-6/SIL-6R signaling in the expression of inducible nitric oxide synthase (iNOS) in murine B16, metastatic melanoma clone F10.9, cells Free Radical Biol. Med. 42 2007 215 227
46. J.H. Kao HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int.: Off. J. Int. Assoc. Study Liver 34 Suppl 1 2014 112 119
47. Y. Kawanishi, N. Hayashi, K. Katayama, K. Ueda, T. Takehara, E. Miyoshi, E. Mita, A. Kasahara, H. Fusamoto, and T. Kamada Tumor necrosis factor-alpha and interferon-gamma inhibit synergistically viral replication in hepatitis B virus-replicating cells J. Med. Virol. 47 1995 272 277
48. U.T. Khan, R. Tanasescu, and C.S. Constantinescu PEGylated IFNbeta-1a in the treatment of multiple sclerosis Expert Opin. Biol. Ther. 15 2015 1077 1084
49. K. Kimura, K. Kakimi, S. Wieland, L.G. Guidotti, and F.V. Chisari Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice J. Virol. 76 2002 10702 10707
50. S. Koh, and A. Bertoletti Circumventing failed antiviral immunity in chronic hepatitis B virus infection: triggering virus-specific or innate-like T cell response? Med. Microbiol. Immunol. 204 2015 87 94
51. R.E. Lanford, B. Guerra, D. Chavez, L. Giavedoni, V.L. Hodara, K.M. Brasky, A. Fosdick, C.R. Frey, J. Zheng, G. Wolfgang, R.L. Halcomb, and D.B. Tumas GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees Gastroenterology 144 2013 1508 1517
52. G.K.K. Lau, T. Piratvisuth, K.X. Luo, P. Marcellin, S. Thongsawat, G. Cooksley, E. Gane, M.W. Fried, W.C. Chow, S.W. Paik, W.Y. Chang, T. Berg, R. Flisiak, P. McCloud, and N. Pluck Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B N. Engl. J. Med. 352 2005 2682 2695
53. W. Leonard Type I cytokines and interferons, an their receptors W. Paul (Ed.), Fundamental Immunology 2013 Lippincott Williams & Wilkins Philadelphia 601 638
54. F.C. Lin, and H.A. Young Interferons: success in anti-viral immunotherapy Cytokine Growth Factor Rev. 25 2014 369 376
55. J. Liu, E. Zhang, Z. Ma, W. Wu, A. Kosinska, X. Zhang, I. Moller, P. Seiz, D. Glebe, B. Wang, D. Yang, M. Lu, and M. Roggendorf Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection PLoS Pathogens 10 2014 e1003856
56. S. Luangsay, M. Ait-Goughoulte, M. Michelet, O. Floriot, M. Bonnin, M. Gruffaz, M. Rivoire, S. Fletcher, H. Javanbakht, J. Lucifora, F. Zoulim, and D. Durantel Expression and functionality of toll- and RIG-like receptors in HepaRG Cells J. Hepatol. 2015 (in press)
57. J. Lucifora, Y. Xia, F. Reisinger, K. Zhang, D. Stadler, X. Cheng, M.F. Sprinzl, H. Koppensteiner, Z. Makowska, T. Volz, C. Remouchamps, W.-M. Chou, W.E. Thasler, N. Hüser, D. Durantel, T.J. Liang, C. Münk, M.H. Heim, J.L. Browning, E. Dejardin, M. Dandri, M. Schindler, M. Heikenwalder, and U. Protzer Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA Science 343 2014 1221 1228
58. Z. Makowska, F.H. Duong, G. Trincucci, D.F. Tough, and M.H. Heim Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo Hepatology 53 2011 1154 1163
59. R. Mao, H. Nie, D. Cai, J. Zhang, H. Liu, R. Yan, A. Cuconati, T.M. Block, J.-T. Guo, and H. Guo Inhibition of hepatitis B virus replication by the host zinc finger antiviral protein PLoS Pathogens 9 2013 e1003494
60. P. Marcellin, G.K.K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z.-M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, M. Diago, S. Gurel, M.-Y. Lai, P. Button, and N. Pluck Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B N. Engl. J. Med. 351 2004 1206 1217
61. P. Marcellin, E.J. Heathcote, M. Buti, E. Gane, R.A. de Man, Z. Krastev, G. Germanidis, S.S. Lee, R. Flisiak, K. Kaita, M. Manns, I. Kotzev, K. Tchernev, P. Buggisch, F. Weilert, O.O. Kurdas, M.L. Shiffman, H. Trinh, M.K. Washington, J. Sorbel, J. Anderson, A. Snow-Lampart, E. Mondou, J. Quinn, and F. Rousseau Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B N. Engl. J. Med. 359 2008 2442 2455
62. H. McClary, R. Koch, F.V. Chisari, and L.G. Guidotti Relative sensitivity of hepatitis B virus and other hepatotropic viruses to the antiviral effects of cytokines J. Virol. 74 2000 2255 2264
63. B.J. McMahon Chronic hepatitis B virus infection Med. Clin. North Am. 98 2014 39 54
64. S. Menne, D.B. Tumas, K.H. Liu, L. Thampi, D. AlDeghaither, B.H. Baldwin, C.A. Bellezza, P.J. Cote, J. Zheng, R. Halcomb, A. Fosdick, S.P. Fletcher, S. Daffis, L. Li, P. Yue, G.H.I. Wolfgang, and B.C. Tennant Sustained efficacy and seroconversion with the Toll-like receptor 7 agonist GS-9620 in the Woodchuck model of chronic hepatitis B J. Hepatol. 62 2015 1237 1245
65. L. Micco, D. Peppa, E. Loggi, A. Schurich, L. Jefferson, C. Cursaro, A.M. Panno, M. Bernardi, C. Brander, F. Bihl, P. Andreone, and M.K. Maini Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B J. Hepatol. 58 2013 225 233
66. A.J. Muir, S. Arora, G. Everson, R. Flisiak, J. George, R. Ghalib, S.C. Gordon, T. Gray, S. Greenbloom, T. Hassanein, J. Hillson, M.A. Horga, I.M. Jacobson, L. Jeffers, K.V. Kowdley, E. Lawitz, S. Lueth, M. Rodriguez-Torres, V. Rustgi, L. Shemanski, M.L. Shiffman, S. Srinivasan, H.E. Vargas, J.M. Vierling, D. Xu, J.C. Lopez-Talavera, and S. Zeuzem A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection J. Hepatol. 61 2014 1238 1246
67. P. Murphy Chemokines W. Paul (Ed.), Fundamental Immunology 2013 Lippincott Williams & Wilkins Philadelphia 681 707
68. S.-I. Nakagawa, Y. Hirata, T. Kameyama, Y. Tokunaga, Y. Nishito, K. Hirabayashi, J. Yano, T. Ochiya, C. Tateno, Y. Tanaka, M. Mizokami, K. Tsukiyama-Kohara, K. Inoue, M. Yoshiba, A. Takaoka, and M. Kohara Targeted induction of interferon-λ in humanized chimeric mouse liver abrogates hepatotropic virus infection PLoS ONE 8 2013 e59611
69. D.R. Nelson, Y. Benhamou, W.L. Chuang, E.J. Lawitz, M. Rodriguez-Torres, R. Flisiak, J.W. Rasenack, W. Kryczka, C.M. Lee, V.G. Bain, S. Pianko, K. Patel, P.W. Cronin, E. Pulkstenis, G.M. Subramanian, J.G. McHutchison, and A.-S. Team Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3 Gastroenterology 139 2010 1267 1276
70. D.H. Nguyen, S. Gummuluru, and J. Hu Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G J. Virol. 81 2007 4465 4472
71. S. Nik-Zainal, D.C. Wedge, L.B. Alexandrov, M. Petljak, A.P. Butler, N. Bolli, H.R. Davies, S. Knappskog, S. Martin, E. Papaemmanuil, M. Ramakrishna, A. Shlien, I. Simonic, Y. Xue, C. Tyler-Smith, P.J. Campbell, and M.R. Stratton Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer Nat. Genet. 46 2014 487 491
72. O.N. Ozes, Z. Reiter, S. Klein, L.M. Blatt, and M.W. Taylor A comparison of interferon-Con1 with natural recombinant interferons-alpha: antiviral, antiproliferative, and natural killer-inducing activities J. Interferon Res. 12 1992 55 59
73. N.E. Pagliaccetti, E.N. Chu, C.R. Bolen, S.H. Kleinstein, and M.D. Robek Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities Virology 401 2010 197 206
74. V. Pasquetto, L.G. Guidotti, K. Kakimi, M. Tsuji, and F.V. Chisari Host-virus interactions during malaria infection in hepatitis B virus transgenic mice J. Exp. Med. 192 2000 529 536
75. V. Pasquetto, S.F. Wieland, S.L. Uprichard, M. Tripodi, and F.V. Chisari Cytokine-sensitive replication of hepatitis B virus in immortalized mouse hepatocyte cultures J. Virol. 76 2002 5646 5653
76. A. Rang, S. Gunther, and H. Will Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells J. Hepatol. 31 1999 791 799
77. B. Rehermann, and A. Bertoletti Immunological aspects of antiviral therapy of chronic hepatitis B virus and hepatitis C virus infections Hepatology 61 2015 712 721
78. B. Reizis, A. Bunin, H.S. Ghosh, K.L. Lewis, and V. Sisirak Plasmacytoid dendritic cells: recent progress and open questions Annu. Rev. Immunol. 29 2011 163 183
79. M.D. Robek, B.S. Boyd, and F.V. Chisari Lambda interferon inhibits hepatitis B and C virus replication J. Virol. 79 2005 3851 3854
80. S.R. Roff, E.N. Noon-Song, and J.K. Yamamoto The significance of interferon-gamma in HIV-1 pathogenesis, therapy, and prophylaxis Front. Immunol. 4 2014 498
81. F. Saade, T. Buronfosse, S. Guerret, P. Pradat, M. Chevallier, F. Zoulim, C. Jamard, and L. Cova In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes J. Viral Hepat. 20 2013 e56 e65
82. A.J. Sadler, and B.R.G. Williams Interferon-inducible antiviral effectors Nat. Rev. Immunol. 8 2008 559 568
83. C.E. Samuel Antiviral actions of interferons Clin. Microbiol. Rev. 14 2001 778 809
84. J.W. Schoggins, S.J. Wilson, M. Panis, M.Y. Murphy, C.T. Jones, P. Bieniasz, and C.M. Rice A diverse range of gene products are effectors of the type I interferon antiviral response Nature 472 2011 481 485
85. C. Seeger, F. Zoulim, and W.S. Mason Hepadnaviruses D.M. Knipe, P.M. Howley (Eds.), Field's Virology 2015 Lippincott Williams & Wilkins Philadelphia 2185
86. N.L.D. Smith, and D.W. Denning Clinical implications of interferon-γ genetic and epigenetic variants Immunology 143 2014 499 511
87. L.M. Snell, and D.G. Brooks New insights into type I interferon and the immunopathogenesis of persistent viral infections Curr. Opin. Immunol. 34 2015 91 98
88. G.M. Subramanian, M. Fiscella, A. Lamouse-Smith, S. Zeuzem, and J.G. McHutchison Albinterferon alpha-2b: a genetic fusion protein for the treatment of chronic hepatitis C Nat. Biotechnol. 25 2007 1411 1419
89. G. Szabo, and J. Petrasek Inflammasome activation and function in liver disease Nat. Rev. Gastroenterol. Hepatol. 12 2015 387 400
90. J.S. Taylor, Q. Zhang, J.G. Julander, A.D. Stoycheva, H. Tan, C.V. Moy, S. Chanda, J.A. Symons, L.N. Beigelman, L.M. Blatt, and J. Hong Development of a hyperglycosylated IFN Alfacon-1 (CIFN): toward bimonthly or monthly dosing for antiviral therapies J. Interferon Cytokine Res. 35 2015 621 633
91. R. Thimme, and M. Dandri Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B? J. Hepatol. 58 2013 205 209
92. S. Tunçbilek Relationship between cytokine gene polymorphisms and chronic hepatitis B virus infection World J. Gastroenterol. 20 2014 6226 6235
93. H.-T. Tzeng, H.-F. Tsai, H.-J. Liao, Y.-J. Lin, L. Chen, P.-J. Chen, and P.-N. Hsu PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model PLoS ONE 7 2012 e39179
94. T.K. Ulland, P.J. Ferguson, and F.S. Sutterwala Evasion of inflammasome activation by microbial pathogens J. Clin. Invest. 125 2015 469 477
95. E. van der Aa, N. van Montfoort, and A.M. Woltman BDCA3+CLEC9A+ human dendritic cell function and development Semin. Cell Dev. Biol. 41 2015 39 48
96. L. Verstrepen, T. Bekaert, T.L. Chau, J. Tavernier, A. Chariot, and R. Beyaert TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme Cell. Mol. Life Sci. 65 2008 2964 2978
97. K. Visvanathan, N.A. Skinner, A.J. Thompson, S.M. Riordan, V. Sozzi, R. Edwards, S. Rodgers, J. Kurtovic, J. Chang, S. Lewin, P. Desmond, and S. Locarnini Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein Hepatology 45 2007 102 110
98. K. Watashi, G. Liang, M. Iwamoto, H. Marusawa, N. Uchida, T. Daito, K. Kitamura, M. Muramatsu, H. Ohashi, T. Kiyohara, R. Suzuki, J. Li, S. Tong, Y. Tanaka, K. Murata, H. Aizaki, and T. Wakita Interleukin-1 and tumor necrosis factor-α trigger restriction of hepatitis B virus infection via a cytidine deaminase activation-induced cytidine deaminase (AID) J. Biol. Chem. 288 2013 31715 31727
99. H. Wedemeyer, C. Yurdaydin, G.N. Dalekos, A. Erhardt, Y. Cakaloglu, H. Degertekin, S. Gurel, S. Zeuzem, K. Zachou, H. Bozkaya, A. Koch, T. Bock, H.P. Dienes, M.P. Manns, and H.S. Group Peginterferon plus adefovir versus either drug alone for hepatitis delta N. Engl. J. Med. 364 2011 322 331
100. H.-L. Weng, B.-E. Wang, J.-D. Jia, W.-F. Wu, J.-Z. Xian, P.R. Mertens, W.-M. Cai, and S. Dooley Effect of interferon-gamma on hepatic fibrosis in chronic hepatitis B virus infection: a randomized controlled study Clin. Gastroenterol. Hepatol. 3 2005 819 828
101. S.F. Wieland, L.G. Guidotti, and F.V. Chisari Intrahepatic induction of alpha/beta interferon eliminates viral RNA-containing capsids in hepatitis B virus transgenic mice J. Virol. 74 2000 4165 4173
102. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, N.H. Segal, C.E. Ariyan, R.-A. Gordon, K. Reed, M.M. Burke, A. Caldwell, S.A. Kronenberg, B.U. Agunwamba, X. Zhang, I. Lowy, H.D. Inzunza, W. Feely, C.E. Horak, Q. Hong, A.J. Korman, J.M. Wigginton, A. Gupta, and M. Sznol Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133
103. Y.C. Xia, J. Lucifora, F. Reisinger, M. Heikenwalder, and U. Protzer Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA" Science 344 2014 1237
104. F.Q. Yang, Y.Y. Yu, G.Q. Wang, J. Chen, J.H. Li, Y.Q. Li, G.R. Rao, G.Y. Mo, X.R. Luo, and G.M. Chen A pilot randomized controlled trial of dual-plasmid HBV DNA vaccine mediated by in vivo electroporation in chronic hepatitis B patients under lamivudine chemotherapy J. Viral Hepat. 19 2012 581 593
105. B. Ye, X. Liu, X. Li, H. Kong, L. Tian, and Y. Chen T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance Cell Death Dis. 6 2015 e1694
106. C. Zannetti, N. Isorce, G. Roblot, S. Luangsay, A. Rozieres, M. Gruffaz, F. Briat, F. Zoulim, T. Henry, D. Durantel, and U.A. Hasan HBV inhibits the aim-2 inflammasome in human kupffer cells J. Hepatol. 58 2013 S140-S140
107. S. Zeuzem, M.S. Sulkowski, E.J. Lawitz, V.K. Rustgi, M. Rodriguez-Torres, B.R. Bacon, M. Grigorescu, A.D. Tice, Y. Lurie, J. Cianciara, A.J. Muir, P.W. Cronin, E. Pulkstenis, G.M. Subramanian, J.G. McHutchison, and A.-S. Team Albinterferon Alfa-2b was not inferior to pegylated interferon-alpha in a randomized trial of patients with chronic hepatitis C virus genotype 1 Gastroenterology 139 2010 1257 1266
108. X. Zhang, Z. Ma, H. Liu, J. Liu, Z. Meng, R. Broering, D. Yang, J.F. Schlaak, M. Roggendorf, and M. Lu Role of Toll-like receptor 2 in the immune response against hepadnaviral infection J. Hepatol. 57 2012 522 528
109. Y. Zheng, L. Zhao, T. Wu, S. Guo, Y. Chen, and T. Zhou Efficacy of consensus interferon in treatment of HbeAg-positive chronic hepatitis B: a multicentre, randomized controlled trial Virol. J. 6 2009 99
110. L. Zitvogel, L. Galluzzi, O. Kepp, M.J. Smyth, and G. Kroemer Type I interferons in anticancer immunity Nat. Rev. Immunol. 15 2015 405 414
111. F. Zoulim, and D. Durantel Antiviral therapies and prospects for a cure of chronic hepatitis B Cold Spring Harb. Perspect. Med. 5 2015 a021501